Form 4: Arcturus Therapeutics Director Jing L. Marantz Receives Annual Stock Option Grant

Arcturus Therapeutics Holdings Inc. director Jing L. Marantz was granted 15,000 stock options with an exercise price of $12.54 as part of her 2025 annual board compensation.

Summary

• Jing L. Marantz, a Director of Arcturus Therapeutics Holdings Inc. (ARCT), was granted 15,000 stock options on June 9, 2025.
• The stock options have an exercise price of $12.54 per share.
• These options will vest monthly over a one-year period from the grant date.
• The options are set to expire on June 9, 2035.
• This grant represents the 2025 annual compensation for her service as a member of the Board of Directors.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with the long-term performance of the company. It is generally viewed as a positive for corporate governance and incentivization, indicating stability in board composition and compensation practices.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Arcturus Therapeutics.
• The 10-year expiration period for the options provides a significant long-term incentive for the director.

Future Outlook

This Form 4 filing reports a routine insider transaction related to director compensation and does not contain forward-looking statements regarding the company's operational or financial outlook, beyond the vesting schedule of the options.

Industry Context

The granting of stock options to board members is a common practice across various industries, particularly in biotechnology and pharmaceuticals, to incentivize long-term commitment and align leadership interests with shareholder returns.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a widely accepted practice in corporate governance, aligning the director's incentives with the company's long-term stock performance.
• The vesting schedule of monthly over one year is a common approach to ensure continued service and commitment from board members.
• The 10-year expiration period for the options is typical for long-term equity incentives granted to executives and directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options creates potential future dilution if exercised, but also enhances the alignment of the director's interests with long-term shareholder value creation.

Next Steps

• The granted options will vest monthly over the next year, allowing the director to exercise them progressively.
• The director may choose to exercise these options at any point before their expiration date of June 9, 2035, subject to vesting.

Key Dates

Recommendation

Keywords

Arcturus Therapeutics, ARCT, stock options, director compensation, insider transaction, Form 4, equity grant, corporate governance